Key Highlights

  • Alpha Tau Medical (NASDAQ:DRTS) fell 10.54% on November 16, 2026, the first session after it released new interim data from its US REGAIN trial in recurrent glioblastoma.
  • All eight treated patients were alive as of November 11, and all six evaluable patients responded, with five complete responses and one partial response.
  • Imaging showed necrosis or suspected necrosis in four of six evaluable patients, and in two of them scans cannot yet separate treatment effect from tumor progression.
  • Median follow-up was 6.9 months, and enrolment continues toward up to 20 patients, which the company says may support a future Marketing submission.

What the REGAIN Data Showed

The update from Alpha Tau Medical (NASDAQ:DRTS), released on November 15 and presented at a neuro-oncology meeting in Philadelphia, covered its Alpha DaRT therapy in patients whose glioblastoma has returned after standard treatment. Alpha DaRT places small sources that release short-range alpha radiation directly inside a tumor, aiming to destroy cancer cells while sparing nearby healthy tissue. Eight patients have been treated so far, and all were alive as of November 11, 2026, with median overall survival not yet reached. Six patients have reached a formal response assessment. All six responded, an objective response rate of 100%, made up of five complete responses and one partial response with a 58% reduction in tumor measurements. The first three patients, first reported in May 2026, are now confirmed complete responses, while responses in the three most recent patients still need confirmation. Median follow-up for the evaluable group is 6.9 months, with a range of 3.1 to 11.6 months. The company also reported 100% feasibility, meaning the planned number of sources was successfully placed in every patient.

Why the Shares Fell Anyway

Headline response rates in a trial of this size are encouraging, but investors focused on the details. Necrosis, which is dead tissue that can follow radiation treatment, or suspected necrosis was seen in four of the six evaluable patients. The company described these cases as asymptomatic. However, in two patients the scans cannot yet distinguish necrosis from tumor growth, and those patients are undergoing further imaging and possibly biopsy. That ambiguity matters because a reclassification of either case as progression would reduce the response rate and raise questions about durability. One patient also had disease progression outside the treated area about nine months after treatment and received additional therapy. On safety, there were no unanticipated serious adverse events, and the one grade 3 seizure reported in May required a 48-hour hospital stay and resolved with steroids. The stock had been down 7.70% during the morning investor call before closing 10.54% lower, in a session when the Nasdaq Composite lost 2.49% and speculative healthcare names were sold.

Path Forward and Key Risks

Glioblastoma remains one of the hardest cancers to treat, and recurrent disease has few effective options, so any therapy showing durable local control would attract attention from regulators and clinicians. Alpha Tau says it will continue enrolment and follow-up toward up to 20 patients and that, based on initial discussions, this cohort may support market submission requirements. Investors in Alpha Tau Medical (NASDAQ:DRTS) should weigh that potential against clear limitations: a very small sample, short follow-up, the absence of a control arm and the interpretive difficulty of imaging after radiation. Further readouts on the two unclear cases, longer survival data and the pace of enrolment will drive the next leg of sentiment. The company is also developing Alpha DaRT in other solid tumors, so progress in additional indications could diversify the Investment case. Funding needs and potential dilution remain standing risks for any clinical-stage company in a weak tape for small-cap biotechnology.

Where Things Stand

Alpha Tau's latest REGAIN data show every evaluable patient responding and every treated patient alive, but scans in two patients cannot yet rule out progression. The 10.54% drop reflects that uncertainty and a broad risk-off session. Clarity on those two cases and enrolment toward 20 patients are the next catalysts.